Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-095011
Filing Date
2025-07-10
Accepted
2025-07-10 16:03:59
Documents
97
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 10-K kalv-20250430.htm   iXBRL 10-K 2786207
2 EX-4.2 kalv-ex4_2.htm EX-4.2 26402
3 EX-5.1 kalv-ex5_1.htm EX-5.1 30552
4 EX-10.23 kalv-ex10_23.htm EX-10.23 953237
5 EX-10.24 kalv-ex10_24.htm EX-10.24 397889
6 EX-19.1 kalv-ex19_1.htm EX-19.1 116056
7 EX-21.1 kalv-ex21_1.htm EX-21.1 16988
8 EX-23.1 kalv-ex23_1.htm EX-23.1 4670
9 EX-31.1 kalv-ex31_1.htm EX-31.1 18559
10 EX-31.2 kalv-ex31_2.htm EX-31.2 16381
11 EX-32.1 kalv-ex32_1.htm EX-32.1 8045
12 EX-32.2 kalv-ex32_2.htm EX-32.2 8864
13 GRAPHIC img28983514_0.jpg GRAPHIC 86613
14 GRAPHIC img48896431_0.jpg GRAPHIC 164897
  Complete submission text file 0000950170-25-095011.txt   12850641

Data Files

Seq Description Document Type Size
15 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20250430.xsd EX-101.SCH 1384244
100 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20250430_htm.xml XML 1812806
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-K | Act: 34 | File No.: 001-36830 | Film No.: 251116356
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)